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Although patients with bacilli resistant to any
drugs were excluded from the trial, the 6-month
regimen would be particularly appropriate for the
treatment of patients with INH-resistant TB. In
contrast to Europe, RIF is licensed for the treatment
of TB in the USA, and there has been a recent
substantial price reduction. We would therefore
encourage consideration of this RIF and MFX
intermittent regimen for the treatment of patients
with INH intolerance or drug resistance in the USA,
and for further implementation studies to evaluate its
utility in other settings.
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In reply
I agree with Phillips and Lipman that the performance
of the recently published 6-month rifapentine (RIF)
and moxifloxacin (MFX) containing regimen in the
RIFAQUIN trial is very encouraging news. Despite
once-weekly dosing for the final 18 weeks with MFX
plus high-dose RIF, the outcomes for the 212 patients
in the experimental 6-month arm were similar to
those for the standard 6-month regimen with daily
dosing throughout.1 The enthusiasm of Phillips and
Lipman for more research into the treatment of
isoniazid (INH) resistant tuberculosis is very wel-
come.
While the RIFAQUIN results are very promising, it
is likely that more research will be needed before this
regimen will be considered standard therapy to
replace the poorly tolerated regimen used in the
United States for INH resistance.2 The currently
approved RIF dose of 600mg twice weekly during the
intensive phase of tuberculosis treatment and the
recommended 600 mg once-weekly regimen for
selected patients during the continuation phase is
rarely used. As most patients with INH resistance or
intolerance will likely have received rifampin (RMP)
during initial therapy, recommendations will need to
address whether it is reasonable to transition patients
to once-weekly RIF and MFX without the full 8
weeks of daily dosing with RIF, MFX, pyrazinamide
and ethambutol used.
The more important potential application of the
RIFAQUIN study is on the global scale, where 9.5%
of nine million cases are estimated to be due to INH-
resistant but RMP-susceptible Mycobacterium tuber-
culosis.3 Caution will be in order in many countries,
as only 49 of the patients were human immunodefi-
ciency virus infected, most with CD4 cell counts well
over 200 cells/mm3, and pregnant women were
excluded from the study. Caution should not be a
barrier, however, to timely completion of the neces-
sary research, given the evidence of acquired RMP
resistance with the current regimens used to treat
INH-resistant tuberculosis.4
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False-positive XpertW MTB/RIF assays and
previous treatment
We thank Steingart et al. for their reply to our case
series and welcome their further analysis.1 It is
reassuring that the performance of Xpertw MTB/
RIF does not seem to be substantially affected by the
phenomenon we described when one looks at a broad
group of patients being investigated for tuberculosis
(TB). However, there is a signal that specificity may
be lower in patients with a history of previous TB, in
that specificity is 100% in cohorts where only 2% of
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patients have a history of TB but declines to 92%
when that proportion increases to 55%.
It is unfortunate that only 36% of studies reported
‘percentage of patients with a history of TB’, and we
suggest that future studies clearly state the treatment
history of all patients and report separately on
specificity for those with previous treatment. Ideally
this would be stratified into those within 6 months, 1
year and 2 years of completing TB treatment. We
have requested access to the data from the two largest
studies2,3 in order to determine specificity separately
for those with a history of TB treatment. Our request
was declined on the basis that it would be a post hoc
analysis of a question the trials were not designed to
answer. We repeat our request to the owners of the
data to provide this analysis, despite the limitations,
in order to provide a clearer picture of the use of
Xpert MTB/RIF in re-treatment cases.
Data from Friedrich et al. suggest that specificity
may be poor soon after TB treatment is completed but
may improve with time;4 in addition, inter-current
lower respiratory tract infection may lead to false-
positive Xpert MTB/RIF years later, as in our index
case.5 We believe the priority for prospective study is
patients being investigated for active TB who
completed treatment within 2 years in order to
determine the specificity, positive predictive value
and positive likelihood ratio for Xpert MTB/RIF in
this cohort.
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